



# Introduction to the PDP Access Group



Heather Kelly  
January 23, 2013

## PDP Definition of Access

---

**“Access” refers to a coordinated set of activities needed to ensure that the products developed will ultimately have an equitable public health impact.**

Achieving that impact requires products that are available, affordable, and acceptable to end-users, and adopted into developing country health systems. The role of PDPs in addressing these four concepts has varied from doing, to facilitating, to advocating for others to take action.

September 2008

---

# Goal and membership

---

- ▶ Goal: to enhance the effectiveness and efficiencies of Product Development Partnerships (PDPs) in the area of access and to contribute to the knowledge base of PDP access work.
  - ▶ 16 members from 13 PDPs and not-for-profit product access organizations
  - ▶ 2 co-chairs and a part-time secretariat (Stefanie)
  - ▶ Emphasis is on sharing knowledge. Each PDP should be equipped to *develop and implement* the strategy that is best for them.
-

# Member PDPs

---



# History and Outputs

---

- ▶ Initial 2008 meeting in Geneva on access issues → paper defining access
  - ▶ DGIS funding in late 2009 allowed the group to commission discussion papers on:
    - ▶ Access strategy
    - ▶ Regulatory
    - ▶ Economics and Financing
    - ▶ Country Decision Making
    - ▶ Pricing
    - ▶ Manufacturing
    - ▶ Pharmacovigilance
    - ▶ Access timelines (ongoing)
    - ▶ Costing of access activities at PDPs (proposed)
    - ▶ Access metrics (proposed)
  - ▶ Website [www.pdpaccess.org](http://www.pdpaccess.org)
-

# Expected Outputs and Outcomes for this meeting

---

## ▶ **Output:**

- ▶ A detailed report summarizing the meeting with conclusions and guidance for further work.

## ▶ **Outcomes:**

- ▶ a better understanding of how to commission, implement, and apply economics and financing studies in a wide range of situations and for varying purposes
  - ▶ a deeper understanding of how country decision-makers use these analyses including e.g. when they would find it more useful for the evaluations to have a product-specific or portfolio/disease approaches.
-